Nrf2 knockdown by shRNA inhibits tumor growth and increases efficacy of chemotherapy in cervical cancer
Cancer Chemotherapy and Pharmacology, 08/18/2011
Ma X et al. – The findings provide evidence that the inhibition of NF–E2–related factor 2 (Nrf2) activity by shRNA might be a promising therapeutic strategy to enhance the efficacy of anticancer drugs and thus can be applied further during the course of chemotherapy in the treatment of cervical cancer.







